Form 4: SPRUCE BIOSCIENCES CEO's Stock Options Repriced

SPRUCE BIOSCIENCES, INC. repriced CEO Javier B. Szwarcberg's stock options, lowering the exercise price to $104.13 per share.

Summary

• Javier B. Szwarcberg, Chief Executive Officer and Director of SPRUCE BIOSCIENCES, INC. (SPRB), reported a change in beneficial ownership.
• The filing details a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025.
• Options with an original exercise price of $344.25 per share were disposed of and new options were acquired at a repriced exercise price.
• The new exercise price for the repriced options is $104.13 per share, which is the thirty (30)-day trailing volume-weighted average price (VWAP) of the Common Stock on the Nasdaq Capital Market on the Repricing Date.
• The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors in continuous service with the company as of the Repricing Date.
• A total of 10,000 derivative securities (Employee Stock Options) were subject to this repricing.
• The vesting schedule, expiration dates, and number of shares underlying the options remain unchanged; vesting commenced January 3, 2022, with 1/4th vested on January 3, 2023, and 1/36th monthly thereafter, expiring on January 2, 2032.
• If an optionholder exercises a repriced option before the end of a one-year retention period (which may be shorter in certain circumstances), the original exercise price per share must be paid.

Sentiment

Score: 3

Explanation: The option repricing, while beneficial for executive incentives, is a strong indicator of significant past stock price underperformance, which is generally negative for existing shareholders. The action itself is a response to a negative event.

Positives

• The repricing significantly lowers the exercise price of the CEO's stock options from $344.25 to $104.13 per share, making them more valuable and potentially 'in-the-money'.
• This action aims to re-incentivize the Chief Executive Officer and other eligible employees/directors, aligning their interests with potential future stock price recovery.

Negatives

• The necessity of a stock option repricing indicates a substantial decline in the company's stock price, as the original options were likely 'underwater' (exercise price higher than market price).
• Option repricing can be viewed negatively by existing shareholders as it effectively resets executive compensation at a lower bar, potentially diluting shareholder value if the stock recovers.

Future Outlook

NA

Industry Context

Stock option repricing is a practice often observed in industries with high stock price volatility, such as biotechnology, where significant declines can render executive and employee options underwater. Companies may undertake repricing to retain and motivate key talent when original equity incentives lose their value, aiming to re-align employee interests with the company's future performance.

Comparison to Industry Standards

• Option repricing, while a tool for executive retention, is often viewed critically by institutional investors and proxy advisors. For example, companies like Biogen or Moderna have faced scrutiny over executive compensation practices following periods of stock underperformance.
• The inclusion of a one-year retention period, requiring the original exercise price if options are exercised early, is a common governance measure to mitigate some shareholder concerns regarding immediate windfalls from repricing.

Corporate Governance

Related Party Transactions

• The repricing of stock options for Javier B. Szwarcberg, who serves as both Chief Executive Officer and a Director, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution if repriced options are exercised; may view the repricing as a negative signal regarding past stock performance and executive accountability.
• Employees and Directors (including CEO): Enhanced incentive and retention due to the repricing of underwater options, making their equity awards more valuable and motivating.

Next Steps

• The repriced stock options will continue to vest according to the original schedule, with 1/36th of the remaining shares vesting on a monthly basis.
• The reporting person may exercise the repriced options after the one-year retention period, or earlier by paying the original exercise price.

Key Dates

Recommendation

The option repricing signals significant past stock underperformance, which is a negative factor. However, the repricing aims to re-incentivize key management, which could be a necessary step for future recovery and talent retention. Given the limited scope of a Form 4 filing, which reports a transaction rather than comprehensive financial results or strategic updates, a 'Hold' recommendation is appropriate. Investors should maintain their current position while awaiting more detailed information on the company's operational and financial performance.

Keywords

SPRUCE BIOSCIENCES, SPRB, Stock Option Repricing, Executive Compensation, Form 4, Insider Transaction, Javier B. Szwarcberg, Equity Incentive Plan